Dr Michelle Kramer and colleagues, the authors of the article "Paliperidone extended-release tablets for the prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study" (J Clin Psychopharmacol. 2007;27:6-14) that appeared in the February issue of the Journal, would like to point out two errors on their part.
On page 7, second column, the third sentence under "Study Design, Randomization, and Blinding": the year "2004" should have been included after "April 13" to clarify that the study was initiated in 2004. The protocol was registered on the website: www.clinicaltrials.gov/.
Therefore, the sentence should read: "Johnson & Johnson Pharmaceutical Research and Development, LLC, funded this study, which was conducted on April 13, 2004 to August 31, 2005 at 45 centers in 6 countries…".
On page 13, Table 4, the correct units for the "Laboratory Measure" "glucose" are "mmol/L", and not "nmol/L" as it appears.
The authors regret these errors.